

Q817G mutation in phosphodiesterase type 5: Conformational profile of the inhibitor Tadalafil

Chemical Biology and Drug Design

93, 419-429

DOI: [10.1111/cbdd.13426](https://doi.org/10.1111/cbdd.13426)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy, 2019, 20, 929-937.	0.9	25
2	In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors. Scientia Pharmaceutica, 2019, 87, 29.	0.7	1
3	Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. Biomedicine and Pharmacotherapy, 2021, 134, 111128.	2.5	59
4	Rutin present in <i>Alibertia edulis</i> extract acts on human platelet aggregation through inhibition of cyclooxygenase/thromboxane. Food and Function, 2021, 12, 802-814.	2.1	9
5	Confinement of the antitumoral drug cisplatin inside edge-functionalized carbon nanotubes and its release near lipid membrane. European Physical Journal D, 2021, 75, 1.	0.6	4
6	Molecular Dynamics Simulation of the Complex of PDE5 and Evodiamine. Life, 2023, 13, 578.	1.1	1